Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ACP3 | P15309 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | KMO | O15229 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | GRM8 | O00222 | 1/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21200270 | 1.00 | MEN1 (0.57) | MEN1KMT2AL3MBTL1HPGDPOLB | |
| SCHEMBL21200078 | 0.87 | MEN1 (0.56) | MEN1KMT2AL3MBTL1HPGDPOLB | |
| SCHEMBL21200076 | 0.87 | MEN1 (0.56) | MEN1KMT2AL3MBTL1HPGDPOLB | |
| SCHEMBL27571912 | 0.85 | L3MBTL1 (0.54) | MEN1KMT2AL3MBTL1HPGDPOLB | |
| SCHEMBL16933041 | 0.84 | ACP3 (0.54) | MEN1KMT2AL3MBTL1HPGDPOLB | |
| SCHEMBL21199799 | 0.83 | KMT2A (0.55) | MEN1KMT2AL3MBTL1HPGDPOLB | |
| SCHEMBL21199796 | 0.83 | KMT2A (0.55) | MEN1KMT2AL3MBTL1HPGDPOLB | |
| SCHEMBL27579047 | 0.83 | L3MBTL1 (0.52) | MEN1KMT2AL3MBTL1HPGDPOLB | |
| SCHEMBL2878386 | 0.83 | L3MBTL1 (0.61) | MEN1KMT2AL3MBTL1HPGDACP3 | |
| SCHEMBL21200551 | 0.83 | L3MBTL1 (0.61) | MEN1KMT2AL3MBTL1HPGDACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227233-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2010-09-15 | — | — | EP | claimed |
| WO-2009073620-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-06-11 | — | — | WO | claimed |
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-3743063-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | Nurix Therapeutics, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| US-20130289083-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| US-8153410-B2 | Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules | FOX CHASE CANCER CENTER (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| US-20090048324-A1 | ALTERNATE MORPHEEIN FORMS OF ALLOSTERIC PROTEINS AS A TARGET FOR THE DEVELOPMENT OF BIOACTIVE MOLECULES | FOX CHASE CANCER CENTER (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053941-A1 | IDO Inhibitors | IDO1, IDO2, INMT | MEN1 2052/4885KMT2A 597/4885L3MBTL1 1178/4885 |
| US-20090048324-A1 | ALTERNATE MORPHEEIN FORMS OF ALLOSTERIC PROTEINS AS A TARGET FOR THE DEVELOPMENT OF BIOACTIVE MOLECULES | BMP2, BMP1, MYOF | MEN1 1437/4885KMT2A 4620/4885L3MBTL1 3729/4885 |
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | MEN1 4135/4885KMT2A 1276/4885L3MBTL1 220/4885 |
| US-20130289083-A1 | IDO Inhibitors | IDO1, IDO2, INMT | MEN1 2267/4885KMT2A 660/4885L3MBTL1 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.